drugset / Trial / NCT04269213
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
Phase 2
Active not recruiting
21 enrolled
Roswell Park Cancer Institute
Jazz Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Timeline
- Start
- 2021-07-29
- Primary completion
- 2025-04-10
- Completion
- 2027-01-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPX-351 | Other / unclassified | — | Intravenous |